908 Devices reports preliminary 2025 revenue growth of 17%

908 Devices Inc. (NASDAQ: MASS) reported preliminary unaudited revenue of approximately $56 million for 2025, representing 17% growth compared to $47.7 million in 2024. The company manufactures handheld chemical analysis tools for health, safety and defense applications.

Fourth quarter 2025 preliminary revenue reached approximately $17.2 million, up from $14.3 million in the same period last year, reflecting 20% growth. The company attributed the quarterly performance to continued strength in U.S. state and local sales channels, international adoption of its VipIR product, and sales to federal and defense customers.

The Burlington, Massachusetts-based company achieved positive Adjusted EBITDA in the fourth quarter, meeting a stated goal. Chief Executive Officer Kevin Knopp said the company "transformed into a stronger, simpler, and more profitable financial model focused on frontline chemical detection."

908 Devices plans to report complete fourth quarter and full year 2025 financial results later this quarter and will provide its 2026 outlook at that time. The preliminary results align with the high end of the company's revenue guidance.

The financial information remains preliminary and unaudited, subject to completion of annual audit procedures and internal reviews. The company noted that actual results may differ materially from these preliminary figures when audited financial statements are completed.

All reported figures represent continuing operations only, following the company's divestiture of its bioprocessing product portfolio in March 2025.

You May Also Be Interested In

• Kura Oncology (KURA) Reiterated at Market Outperform by Citizens Post Q2 Results
• Amazon.com (AMZN) Reiterated at Market Outperform by Citizens as Frontier Models Grow
• Morgan Stanley Starts Tier IV Inc (593A:JP) at Overweight